Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etilamfetamine is a synthetic stimulant drug of the phenethylamine and amphetamine chemical classes. It is structurally related to amphetamine and methamphetamine but contains an ethyl group instead of a methyl group on the nitrogen atom. Etilamfetamine acts as a central nervous system stimulant by promoting the release of monoamines such as dopamine and norepinephrine from presynaptic nerve terminals. It was previously used in some countries for indications such as depression and narcolepsy but has largely been discontinued due to concerns about abuse potential and side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Etilamfetamine.